Literature DB >> 28761590

Conservative treatment of upper urinary tract carcinoma: Long-term results.

Andrea Orosa Andrada1, Inés Laso García1, Fernando Arias Fúnez1, Francisco Donis Canet1, Gemma Duque Ruiz1, Victoria Gómez Dos Santos1, Francisco Javier Burgos Revilla1.   

Abstract

INTRODUCTION: We sought to assess the long-term results of conservative treatment for upper urinary tract carcinoma (UUTC) with regard to tumour recurrence and preservation of renal unit.
METHODS: From October 1987 to January 2014, 65 patients (median age 68 years) were diagnosed with UUTC and underwent endoscopic and open surgical techniques. Thirteen patients had bilateral disease and one had a single kidney. The primary approach was endoscopic in 37 reno-ureteral units (20 percutaneous resections, 17 ureteroscopies ). Open surgery was performed in 19 cases. A total of 20 patients received mitomycin C.
RESULTS: Superficial stage pTa or T1 was noted in 37 patients, infiltrating stage pT2 and pT3 in seven and inverted papilloma in one. The stage of the tumour was impossible to classify in 20. With a median followup of 75.12 months (interquartile range [IQR] 144.71-17.41), the kidney preservation, recurrence, specific survival, and global survival rates were 78.5% (51/65), 40.0% (26/65), 92.3% (60/65), and 69.2% (45/65), respectively. From the patients who had recurrence, 15 were salvaged with radical nephroureterectomy (RNU). The bladder tumour recurrence rate after the surgery was 30.76% (20/65). At the end of the followup, five patients had died of UUTC progression and 16 from other causes. Postoperative complications included one case of fistula, one case of stricture, and one case of nephrectomy due to bleeding.
CONCLUSIONS: In selected cases, conservative management is a safe and feasible alternative to RNU, with the advantage of renal unit preservation.

Entities:  

Year:  2017        PMID: 28761590      PMCID: PMC5519388          DOI: 10.5489/cuaj.4173

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  26 in total

1.  Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter.

Authors:  Claudio Jeldres; Giovanni Lughezzani; Maxine Sun; Hendrik Isbarn; Shahrokh F Shariat; Lars Budaus; Jean-Baptiste Lattouf; Hugues Widmer; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

2.  Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience.

Authors:  Mark L Cutress; Grant D Stewart; Edward C G Tudor; Eric A Egong; Simon Wells-Cole; Simon Phipps; Ben G Thomas; Antony C P Riddick; S Alan McNeill; David A Tolley
Journal:  J Urol       Date:  2012-12-07       Impact factor: 7.450

3.  Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression.

Authors:  I Iborra; E Solsona; J Casanova; J V Ricós; J Rubio; M A Climent
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

Review 4.  Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.

Authors:  Thomas Seisen; Benoit Peyronnet; Jose Luis Dominguez-Escrig; Harman M Bruins; Cathy Yuhong Yuan; Marko Babjuk; Andreas Böhle; Maximilian Burger; Eva M Compérat; Nigel C Cowan; Eero Kaasinen; Joan Palou; Bas W G van Rhijn; Richard J Sylvester; Richard Zigeuner; Shahrokh F Shariat; Morgan Rouprêt
Journal:  Eur Urol       Date:  2016-07-28       Impact factor: 20.096

5.  Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study.

Authors:  Pierre Colin; Adil Ouzzane; Géraldine Pignot; Emmanuel Ravier; Sébastien Crouzet; Mehdi M Ariane; Marie Audouin; Yann Neuzillet; Baptiste Albouy; Sophie Hurel; Fabien Saint; Julien Guillotreau; Laurent Guy; Pierre Bigot; Alexandre De La Taille; Frédéric Arroua; Charles Marchand; Alexandre Matte; Pierre O Fais; Morgan Rouprêt
Journal:  BJU Int       Date:  2012-03-06       Impact factor: 5.588

6.  European guidelines on upper tract urothelial carcinomas: 2013 update.

Authors:  Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard Sylvester; Max Burger; Nigel Cowan; Andreas Böhle; Bas W G Van Rhijn; Eero Kaasinen; Joan Palou; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2013-03-19       Impact factor: 20.096

7.  Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.

Authors:  Matthew G Kaag; Rebecca L O'Malley; Padraic O'Malley; Guilherme Godoy; Mang Chen; Marc C Smaldone; Ronald L Hrebinko; Jay D Raman; Bernard Bochner; Guido Dalbagni; Michael D Stifelman; Samir S Taneja; William C Huang
Journal:  Eur Urol       Date:  2010-06-25       Impact factor: 20.096

8.  Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma.

Authors:  Morgan Rouprêt; Vincent Hupertan; Olivier Traxer; Guillaume Loison; Emmanuel Chartier-Kastler; Pierre Conort; Marc-Olivier Bitker; Bernard Gattegno; François Richard; Olivier Cussenot
Journal:  Urology       Date:  2006-06       Impact factor: 2.649

9.  Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience.

Authors:  Siamak Daneshmand; Marcus L Quek; Jeffry L Huffman
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

10.  Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.

Authors:  Mark L Cutress; Grant D Stewart; Simon Wells-Cole; Simon Phipps; Ben G Thomas; David A Tolley
Journal:  BJU Int       Date:  2012-05-07       Impact factor: 5.588

View more
  1 in total

1.  Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the Pandemic of COVID-19?

Authors:  Petrisor Geavlete; Razvan Multescu; Bogdan Geavlete
Journal:  Eur Urol       Date:  2022-01-19       Impact factor: 24.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.